Neurocrine Biosciences (NBIX) Competitors $121.02 +0.75 (+0.62%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$116.10 -4.91 (-4.06%) As of 05/16/2025 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX vs. ALNY, BIIB, UTHR, INCY, BMRN, EXEL, EXAS, HALO, RGEN, and MDGLShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Repligen (RGEN), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Alnylam Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Exelixis Exact Sciences Halozyme Therapeutics Repligen Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends. Which has more risk and volatility, ALNY or NBIX? Alnylam Pharmaceuticals has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Is ALNY or NBIX more profitable? Neurocrine Biosciences has a net margin of 14.49% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Neurocrine Biosciences' return on equity of 13.38% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% Neurocrine Biosciences 14.49%13.38%9.73% Does the MarketBeat Community prefer ALNY or NBIX? Alnylam Pharmaceuticals received 123 more outperform votes than Neurocrine Biosciences when rated by MarketBeat users. However, 77.68% of users gave Neurocrine Biosciences an outperform vote while only 76.32% of users gave Alnylam Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes116776.32% Underperform Votes36223.68% Neurocrine BiosciencesOutperform Votes104477.68% Underperform Votes30022.32% Does the media refer more to ALNY or NBIX? In the previous week, Neurocrine Biosciences had 9 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 29 mentions for Neurocrine Biosciences and 20 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.21 beat Neurocrine Biosciences' score of 1.13 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Neurocrine Biosciences 18 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, ALNY or NBIX? Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.35B15.84-$278.16M-$2.09-136.51Neurocrine Biosciences$2.41B4.96$341.30M$2.9541.02 Do institutionals & insiders hold more shares of ALNY or NBIX? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer ALNY or NBIX? Alnylam Pharmaceuticals currently has a consensus price target of $319.17, suggesting a potential upside of 11.87%. Neurocrine Biosciences has a consensus price target of $162.00, suggesting a potential upside of 33.86%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77Neurocrine Biosciences 0 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.86 SummaryNeurocrine Biosciences beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.98B$2.88B$5.36B$8.52BDividend YieldN/A1.94%4.95%4.12%P/E Ratio36.7830.7327.0220.02Price / Sales4.96408.24390.42119.66Price / Cash34.35168.6838.2534.62Price / Book4.663.066.764.60Net Income$341.30M-$72.35M$3.23B$248.70M7 Day Performance4.59%3.92%4.85%5.15%1 Month Performance19.37%8.37%9.89%13.70%1 Year Performance-14.95%-28.71%14.87%6.80% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.949 of 5 stars$121.02+0.6%$162.00+33.9%-14.7%$11.98B$2.41B36.781,200Trending NewsALNYAlnylam Pharmaceuticals4.2998 of 5 stars$270.19+7.6%$319.17+18.1%+88.7%$35.23B$2.35B-124.512,000Trending NewsBIIBBiogen4.922 of 5 stars$124.40+5.3%$191.30+53.8%-45.4%$18.23B$9.82B11.128,720Trending NewsAnalyst RevisionUTHRUnited Therapeutics4.9925 of 5 stars$310.80+3.1%$392.00+26.1%+12.2%$14.02B$2.99B13.65980Trending NewsINCYIncyte4.8965 of 5 stars$60.85+3.2%$73.53+20.8%+11.3%$11.78B$4.41B225.382,320Trending NewsBMRNBioMarin Pharmaceutical4.9947 of 5 stars$61.37+4.3%$93.45+52.3%-23.0%$11.77B$2.95B27.903,080Trending NewsEXELExelixis4.0857 of 5 stars$36.98+2.2%$37.59+1.6%+113.8%$10.19B$2.17B20.891,220Trending NewsAnalyst ForecastInsider TradeOptions VolumeEXASExact Sciences4.7029 of 5 stars$53.40+3.4%$70.90+32.8%+8.6%$10.07B$2.83B-9.596,400Positive NewsHALOHalozyme Therapeutics4.8784 of 5 stars$66.58+1.1%$63.78-4.2%+14.6%$8.20B$1.08B19.41390Analyst DowngradeRGENRepligen4.9048 of 5 stars$133.72+8.5%$173.25+29.6%-26.0%$7.51B$650.43M-262.202,020Positive NewsGap UpMDGLMadrigal Pharmaceuticals4.6451 of 5 stars$300.76+2.1%$416.33+38.4%+34.0%$6.68B$317.38M-11.9990Positive News Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Incyte Competitors BioMarin Pharmaceutical Competitors Exelixis Competitors Exact Sciences Competitors Halozyme Therapeutics Competitors Repligen Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBIX) was last updated on 5/17/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.